

**The aryl hydrocarbon receptor controls mesenchymal stromal cell-mediated immunomodulation via ubiquitination of eukaryotic elongation factor-2 kinase**

Enkhmaa Lkhagva-Yondon<sup>1,3,7</sup>, Myeong Seong Seo<sup>1,3,7</sup>, Yena Oh<sup>1,2</sup>, Jong Hun Jung<sup>1,3</sup>, Eunhae Jeon<sup>1,2</sup>, Kwangmin Na<sup>1</sup>, Hyun Seung Yoo<sup>1,2</sup>, Woo Chul Kim<sup>4</sup>, Charlotte Esser<sup>5</sup>, Sun U Song<sup>1,2,6</sup>, and Myung-Shin Jeon<sup>1,2,3,6</sup>

<sup>1</sup> Translational Research Center, Inha University Hospital, Incheon 22332, Republic of Korea

<sup>2</sup> Department of Molecular Biomedicine, College of Medicine Inha University, Incheon 22212, Republic of Korea

<sup>3</sup> Program in Biomedical Science & Engineering Inha University, Incheon 22212, Republic of Korea

<sup>4</sup> Department of Radiation Oncology, Inha University Hospital, Incheon 22332, Republic of Korea


<sup>5</sup> IUF-Leibniz Research Institute for Environmental Medicine, Düsseldorf 40021, Germany

<sup>6</sup> SCM Lifescience, Incheon 21999, Republic of Korea

Correspondence: Prof. Myung-Shin Jeon, Translational Research Center, Inha University Hospital, College of Medicine, B/306 Jungseok Bldg., 366 Seohae-daero, Jung-Gu, Incheon 22332, Korea. (Tel.) +82-32-890-3682; (Fax) +82-32-890-2462; (E-mail) [msjeon@inha.ac.kr](mailto:msjeon@inha.ac.kr)


<sup>7</sup> These authors contributed equally to this work.

## Supplement Figure 1




**Fig. 1 Effect of *Ahr*<sup>-/-</sup> MSC on T cell proliferation in the presence of iNOS inhibitor**

Lymphocytes were stained with CFSE and stimulated with 1  $\mu$ g/mL anti-CD3 and anti-CD28 Abs in the presence of 1 mM L-NMMA, an iNOS inhibitor. (A) After 72 h, T-cell divisions were analyzed by flow cytometry. (B) NO production was measured in the culture media using ELISA.

**Supplement Figure 2****Fig. 2 Effect of *Ahr* deficiency on glucose transporters**

WT- and KO-MSCs were stimulated by TNF- $\alpha$ , IFN- $\gamma$ , and IL-1 $\beta$ . After 24 h, the expression of GLUT1 and GLUT3 proteins was measured by western blotting.


## Supplement Figure 2



**Fig. 3 Co-localization of AHR and eEF2K with ER marker ERp72**


(A) MSCs were stained with anti-AHR (green) and anti-eEF2K (red) antibodies and co-localization was measured by immunofluorescence. (B) MSCs were stained with anti-AHR (green) and anti-ERp72 (red) antibodies and immunofluorescence measured co-localization. DAPI was used to count nuclear staining. All experiments were repeated at least twice, and similar results were obtained.

## Supplement Figure 4

**Fig. 4 Genotyping, characterization, and differentiation of MSCs**

(A) Genotyping of *Ahr*. Using phenol extraction, genomic DNA was isolated from *Ahr* wild-type (WT)- and knockout (KO)-MSCs. *Ahr* gene deficiency was confirmed by genomic PCR. (B) MSCs were characterized according to cell surface markers, such as positive for CD44, CD105, and Sca-1 and negative for CD14, CD34, and MHC class II. (C) Three lineage differentiation of MSCs was performed. All experiments were repeated at least twice, and similar results were obtained.

## Supplement Figure 5

**Fig. 5 Immunofluorescence staining control**

2<sup>nd</sup> Antibodies were stained alone as a negative control.

**Supplemental Table 1 Antibodies**

<b>Antibody</b>	<b>Source</b>	<b>Identifier</b>	<b>Application</b>
Actin	Santa Cruz ( CA, USA)	#47778	WB (1/1,000)
AhR	Proteintech (Rosemont, IL, USA)	#17840-I-AP	WB (1/1,000), IF (1/100)
b-TRCP	Cell Signaling (Boston, MA, USA)	#11984S	WB (1/1,000)
CD14	BD Biosciences ( NJ, USA)	#560638	FC (1/100)
CD34	Biologend (CA, USA)	#128611	FC (1/100)
CD44	BD Biosciences ( NJ, USA)	#553133	FC (1/100)
CD105	Biologend (CA, USA)	#120407	FC (1/100)
CUL4B	Proteintech (Rosemont, IL, USA)	#12916-1-AP	WB (1/1,000), IP (4 µg)
eEF2	Cell Signaling (Boston, MA, USA)	#2332S	WB (1/1,000)
eEF2k	Santa Cruz ( CA, USA)	#390710	WB (1/500), IP (4 µg), IF (1/100)
eIF2a	Cell Signaling (Boston, MA, USA)	#9722S	WB (1/1,000)
ERp72	Cell Signaling (Boston, MA, USA)	#5033S	IF 1/100
GLUT1	Abcam (Cambridge, UK)	#115730	WB (1/1,000)
GLUT3	Proteintech (Rosemont, IL, USA)	#20403-1-AP	WB (1/1,000)
INOS	Cell Signaling (Boston, MA, USA)	#13120	WB (1/2000), IP (4 µg)
MHC II	BD Biosciences (NJ, USA)	#553623	FC (1/100)
p-eEF2 (Thr56)	Cell Signaling (Boston, MA, USA)	#2331S	WB (1/1,000)
p-eEF2k (S366)	Cell Signaling (Boston, MA, USA)	#3691	WB (1/1,000)
p-eIF2a (S51)	Cell Signaling (Boston, MA, USA)	#3597S	WB (1/1,000)
STAT1	Cell Signaling (Boston, MA, USA)	#14944	WB (1/1,000)
p-STAT1 (S727)	Cell Signaling (Boston, MA, USA)	#8826	WB (1/1,000)
Ubiquitin	Santa Cruz ( CA, USA)	#8017	WB (1/1,000)
Mouse IgG1-HRP	Cell Signaling (Boston, MA, USA)	#7076S	WB (1/1,0000)
Rabbit Ig-G1-HRP	Invitrogen (Carlsbad, CA, USA)	#31460	WB (1/1,0000)

**Supplemental Table 2. Chemical lists**

<b>Name</b>	<b>Source</b>	<b>Identifier</b>
A-484954	Sigma (St Louis, MO, USA)	#324516
Choloroquine diphosphate salt	Sigma (St Louis, MO, USA)	#C6628
CH-223191	Sigma (St Louis, MO, USA)	#C8124
Cycloheximide	Sigma (St Louis, MO, USA)	#C7698
6-formylindolo [3, 2-b] carbazole	Sigma (St Louis, MO, USA)	#SML1489
L-NMMA	Sigma (St Louis, MO, USA)	#53308-83-1
MG132	Sigma (St Louis, MO, USA)	#474790
3-Methylcholanthrene	Sigma (St Louis, MO, USA)	#442388
<b>Adipogenic differentiation</b>		
Dexamethasone	Sigma (St Louis, MO, USA)	#D8893
Indomethacin	Sigma (St Louis, MO, USA)	#17378
Insulin	Sigma (St Louis, MO, USA)	#19278
Isobutylmethylxanthine	Sigma (St Louis, MO, USA)	#17018
<b>Chondrogenic differentiation</b>		
Ascorbic acid	Sigma (St Louis, MO, USA)	#A4403
Dexamethasone	Sigma (St Louis, MO, USA)	#D8893
ITS Premix	BD Bioscience	#354352
L-Proline	Sigma (St Louis, MO, USA)	#P5607
TGF- $\beta$ 1	R&D Systems	#240-B
TGF- $\beta$ 3	R&D Systems	#243-B
<b>Osteogenic differentiation</b>		
Ascorbic acid	Sigma (St Louis, MO, USA)	#A4403
$\beta$ -glycerolphosphate	Sigma (St Louis, MO, USA)	#G9422
Dexamethasone	Sigma (St Louis, MO, USA)	#D8893
dibutyryl cyclin AMP	Sigma (St Louis, MO, USA)	#D067



**Supplemental Table 3. GVHD Clinical scores**

Symptoms	Severity scores		
	normal	mild	severe
Ruffled hair	0	1	2
Hunched back	0	1	2
Diarrhea	0	1	2
Damaged skin	0	1	2
Ascites	0	1	2
Total			10
Dead			10